LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Impact of Respiratory Developmental Stage on Sensitivity to Late Effects of Radiation in Pediatric Cancer Survivors.

    Khan, Fatima / Williams, Annalynn M / Weiner, Daniel J / Constine, Louis S

    Advances in radiation oncology

    2019  Volume 5, Issue 3, Page(s) 426–433

    Abstract: Purpose: Pulmonary dysfunction is a prevalent and potentially debilitating late effect of pediatric cancer treatment. We postulated that age, as a surrogate for respiratory developmental status, might be associated with vulnerability to pulmonary injury. ...

    Abstract Purpose: Pulmonary dysfunction is a prevalent and potentially debilitating late effect of pediatric cancer treatment. We postulated that age, as a surrogate for respiratory developmental status, might be associated with vulnerability to pulmonary injury.
    Materials and methods: Sixty-one children treated with lung radiation at our institution who had undergone a pulmonary function test (PFT) between 1995 and 2016 were analyzed. Data collection included age at diagnosis and treatment, radiation dose and location, spirometry, and plethysmography results. PFTs were normalized according to age, sex, height, and ethnicity, and transformed into standardized z-scores. Obstructive disease was defined as forced expiratory volume in 1 second
    Results: At a mean age of 24 years (range, 12-31) and time from radiation of 9 years (range, 1-20), the cumulative incidence of any pulmonary abnormality was 34.4%. Among patients with an abnormal PFT, diffusing and restrictive abnormalities were most common (57.1% and 52.4%). When stratified by age at radiation treatment, 66.7% of patients <5 years had a PFT abnormality, compared with 47.6% for aged 5 to 13 and 20.6% for patients >13. Compared with patients >13 years, those <5 years and 5 to 13 years at radiation treatment had a significantly increased risk of an abnormal PFT with an odds ratio of 7.71 (95% confidence interval, 1.17, 51.06) and 3.51 (95% confidence interval, 1.06, 11.57), respectively (
    Conclusions: PFT abnormalities were common among our cohort of childhood cancer survivors treated with lung radiation. Younger age at treatment is associated with an increased risk of developing pulmonary dysfunction, presumably owing to developmental immaturity.
    Language English
    Publishing date 2019-12-11
    Publishing country United States
    Document type Journal Article
    ISSN 2452-1094
    ISSN 2452-1094
    DOI 10.1016/j.adro.2019.12.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

    Williams, Annalynn M / Zent, Clive S / Janelsins, Michelle C

    British journal of haematology

    2016  Volume 174, Issue 6, Page(s) 835–846

    Abstract: Cancer-related cognitive impairment (CRCI) is an important clinical problem for cancer patients and survivors. In this review, we summarize studies investigating the occurrence of impaired cognition in patients with haematological malignancies. Most ... ...

    Abstract Cancer-related cognitive impairment (CRCI) is an important clinical problem for cancer patients and survivors. In this review, we summarize studies investigating the occurrence of impaired cognition in patients with haematological malignancies. Most published studies focus on survivors of childhood acute lymphoblastic leukaemia and primary central nervous system lymphoma. We also discuss studies conducted in acute myeloid leukaemia, myelodysplastic syndromes, chronic myeloid leukaemia, Hodgkin lymphoma (HL), non-HL and chronic lymphocytic leukaemia. Although research in this area is still emerging, it appears that a subset of chemotherapy-treated haematological malignancy survivors experience CRCI. Future research should focus on expanding the literature reviewed here with larger studies appropriately powered to assess cognition via objective and subjective measures in a longitudinal fashion to tease apart the impact of disease and the various forms of cancer treatment.
    MeSH term(s) Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Cognition/drug effects ; Cognition/radiation effects ; Cognitive Dysfunction/diagnosis ; Cognitive Dysfunction/epidemiology ; Cognitive Dysfunction/etiology ; Cognitive Dysfunction/therapy ; Combined Modality Therapy/adverse effects ; Combined Modality Therapy/methods ; Disease Management ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/epidemiology ; Humans ; Risk Factors
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2016-09
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Review
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.14211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

    Feldman, Darren R / Ardeshir-Rouhani-Fard, Shirin / Monahan, Patrick / Sesso, Howard D / Fung, Chunkit / Williams, Annalynn M / Hamilton, Robert J / Vaughn, David J / Beard, Clair J / Cook, Ryan / Zaid, Mohammad Abu / Lipshultz, Steven E / Einhorn, Lawrence H / Oeffinger, Kevin C / Travis, Lois B / Fossa, Sophie D

    Clinical genitourinary cancer

    2018  Volume 16, Issue 4, Page(s) e761–e769

    Abstract: Background: Testicular cancer survivors (TCSs) are at increased risk of cardiovascular disease (CVD) after cisplatin-based chemotherapy (CBCT). Identifying at-risk survivors would allow early intervention, but risk prediction tools such as the ... ...

    Abstract Background: Testicular cancer survivors (TCSs) are at increased risk of cardiovascular disease (CVD) after cisplatin-based chemotherapy (CBCT). Identifying at-risk survivors would allow early intervention, but risk prediction tools such as the Framingham Risk Score (FRS) have not been applied to TCSs given modern chemotherapy.
    Methods: TCSs > 1 year post-CBCT were evaluated. Associations between FRS and clinical, socioeconomic, and lifestyle measures and treatment regimen (4 cycles, etoposide and cisplatin [EP × 4]); 3 or 4 cycles, bleomycin plus EP (BEP × 3, BEP × 4) were analyzed with general linear multivariable models. Controls from the National Health and Nutrition Examination Survey were matched 1:1 to TCSs by age, race, and education with differences in mean FRS evaluated with 2-sided t tests.
    Results: Of 787 TCSs (median age, 37.3 years; median follow-up, 4.2 years), 284, 342, and 161 received EP × 4, BEP × 3, or BEP × 4, respectively. TCSs had higher median systolic blood pressure (126 vs. 119 mm Hg; P < .001), but fewer were smokers (8.4% vs. 28.2%; P < .001) than controls. In multivariable analysis, no significant differences in FRS between EP × 4, BEP × 3, and BEP × 4 were observed, but less than college education (P < .001) and lack of vigorous exercise (P = .006) were associated with higher FRS. Mean FRS did not differ between TCSs and controls (6.8% vs. 7.3%; P = .67).
    Conclusion: This is the first study to apply the office-based FRS to TCSs. Chemotherapy regimen (BEP × 3 vs. EP × 4) was not associated with FRS, but less educated and less vigorously active patients had higher FRS, and present a high-risk subgroup for intense follow-up and counseling.
    MeSH term(s) Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/adverse effects ; Bleomycin/therapeutic use ; Cancer Survivors ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/epidemiology ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Humans ; Male ; Middle Aged ; Risk Factors ; Testicular Neoplasms/drug therapy ; Young Adult
    Chemical Substances Bleomycin (11056-06-7) ; Etoposide (6PLQ3CP4P3) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2018-02-05
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2018.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

    Janelsins, Michelle C / Heckler, Charles E / Peppone, Luke J / Ahles, Tim A / Mohile, Supriya G / Mustian, Karen M / Palesh, Oxana / O'Mara, Ann M / Minasian, Lori M / Williams, Annalynn M / Magnuson, Allison / Geer, Jodi / Dakhil, Shaker R / Hopkins, Judith O / Morrow, Gary R

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2018  , Page(s) JCO2018786624

    Abstract: Purpose: Cancer-related cognitive impairment (CRCI) is an important clinical problem in patients with breast cancer receiving chemotherapy. Nationwide longitudinal studies are needed to understand the trajectory and severity of CRCI in specific ... ...

    Abstract Purpose: Cancer-related cognitive impairment (CRCI) is an important clinical problem in patients with breast cancer receiving chemotherapy. Nationwide longitudinal studies are needed to understand the trajectory and severity of CRCI in specific cognitive domains.
    Patients and methods: The overall objective of this nationwide, prospective, observational study conducted within the National Cancer Institute Community Clinical Oncology Research Program was to assess trajectories in specific cognitive domains in patients with breast cancer (stage I-IIIC) receiving chemotherapy, from pre- (A1) to postchemotherapy (A2) and from prechemotherapy to 6 months postchemotherapy (A3); controls were assessed at the same time-equivalent points. The primary aim assessed visual memory using the Cambridge Neuropsychological Test Automated Battery Delayed Match to Sample test by longitudinal mixed models including A1, A2, and A3 and adjusting for age, education, race, cognitive reserve score, and baseline anxiety and depressive symptoms. We also assessed trajectories of CRCI in other aspects of memory as well as in attention and executive function with computerized, paper-based, and telephone-based cognitive tests.
    Results: In total, 580 patients with breast cancer (mean age, 53.4 years) and 363 controls (mean age, 52.6 years) were assessed. On the Delayed Match to Sample test, the longitudinal mixed model results revealed a significant group-by-time effect ( P < .005); patients declined over time from prechemotherapy (A1) to 6 months postchemotherapy (A3; P = .005), but controls did not change ( P = .426). The group difference between patients and controls was also significant, revealing declines in patients but not controls ( P = .017). Several other models of computerized, standard, and telephone tests indicated significantly worse performance by patients compared with controls from pre- to postchemotherapy and from prechemotherapy to 6 months postchemotherapy.
    Conclusion: This nationwide study showed CRCI in patients with breast cancer affects multiple cognitive domains for at least 6 months postchemotherapy.
    Language English
    Publishing date 2018-09-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2018.78.6624
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

    Zaid, Mohammad Abu / Gathirua-Mwangi, Wambui G / Fung, Chunkit / Monahan, Patrick O / El-Charif, Omar / Williams, Annalynn M / Feldman, Darren R / Hamilton, Robert J / Vaughn, David J / Beard, Clair J / Cook, Ryan / Althouse, Sandra K / Ardeshir-Rouhani-Fard, Shirin / Dinh, Paul C / Sesso, Howard D / Einhorn, Lawrence H / Fossa, Sophie D / Travis, Lois B

    Journal of the National Comprehensive Cancer Network : JNCCN

    2018  Volume 16, Issue 3, Page(s) 257–265

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Adult ; Biomarkers ; Cancer Survivors ; Case-Control Studies ; Comorbidity ; Genetic Variation ; Humans ; Male ; Middle Aged ; Neoplasms, Germ Cell and Embryonal ; Prevalence ; Prognosis ; Risk Factors ; Socioeconomic Factors ; Testicular Neoplasms/epidemiology ; Testicular Neoplasms/genetics ; Testicular Neoplasms/metabolism ; Testicular Neoplasms/therapy ; Young Adult
    Chemical Substances Biomarkers
    Language English
    Publishing date 2018-03-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2017.7046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

    Fung, Chunkit / Sesso, Howard D / Williams, Annalynn M / Kerns, Sarah L / Monahan, Patrick / Abu Zaid, Mohammad / Feldman, Darren R / Hamilton, Robert J / Vaughn, David J / Beard, Clair J / Kollmannsberger, Christian K / Cook, Ryan / Althouse, Sandra / Ardeshir-Rouhani-Fard, Shirin / Lipshultz, Steve E / Einhorn, Lawrence H / Fossa, Sophie D / Travis, Lois B

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2017  Volume 35, Issue 11, Page(s) 1211–1222

    Abstract: Purpose To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). Methods Nine hundred ... ...

    Abstract Purpose To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). Methods Nine hundred fifty-two TCSs > 1 year postchemotherapy underwent physical examination and completed a questionnaire. Multinomial logistic regression estimated AHOs odds ratios (ORs) in relation to age, cumulative cisplatin and/or bleomycin dose, time since chemotherapy, sociodemographic factors, and health behaviors. Results Median age at evaluation was 37 years; median time since chemotherapy was 4.3 years. Chemotherapy consisted largely of BEPX3 (38.2%), EPX4 (30.9%), and BEPX4 (17.9%). None, one to two, three to four, or five or more AHOs were reported by 20.4%, 42.0%, 25.1%, and 12.5% of TCSs, respectively. Median number after EPX4 or BEPX3 was two (range, zero to nine and zero to 11, respectively; P > .05) and two (range, zero to 10) after BEPX4. When comparing individual AHOs for EPX4 versus BEPX3, Raynaud phenomenon (11.6% v 21.4%; P < .01), peripheral neuropathy (29.2% v 21.4%; P = .02), and obesity (25.5% v 33.0%; P = .04) differed. Larger cumulative bleomycin doses (OR, 1.44 per 90,000 IU) were significantly associated with five or more AHOs. Increasing age was a significant risk factor for one to two, three to four, or five or more AHOs versus zero AHOs (OR, 1.22, 1.50, and 1.87 per 5 years, respectively; P < .01); vigorous physical activity was protective (OR, 0.62, 0.51, and 0.41, respectively; P < .05). Significant risk factors for three to four and five or more AHOs included current (OR, 3.05 and 3.73) or former (OR, 1.61 and 1.76) smoking ( P < .05). Self-reported health was excellent/very good in 59.9% of TCSs but decreased as AHOs increased ( P < .001). Conclusion Numbers of AHOs after EPX4 or BEPX3 appear similar, with median follow-up of 4.3 years. A healthy lifestyle was associated with reduced number of AHOs.
    MeSH term(s) Adult ; Age Factors ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bleomycin/administration & dosage ; Bleomycin/adverse effects ; Canada/epidemiology ; Case-Control Studies ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Etoposide/administration & dosage ; Exercise ; Health Status ; Hearing Loss/chemically induced ; Hearing Loss/epidemiology ; Humans ; Long Term Adverse Effects/chemically induced ; Long Term Adverse Effects/epidemiology ; Male ; Middle Aged ; Obesity/chemically induced ; Obesity/epidemiology ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/epidemiology ; Prevalence ; Protective Factors ; Raynaud Disease/chemically induced ; Raynaud Disease/epidemiology ; Risk Factors ; Smoking/epidemiology ; Surveys and Questionnaires ; Survivors/statistics & numerical data ; Testicular Neoplasms/drug therapy ; Tinnitus/chemically induced ; Tinnitus/epidemiology ; United States/epidemiology ; Young Adult
    Chemical Substances Bleomycin (11056-06-7) ; Etoposide (6PLQ3CP4P3) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2017-02-27
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2016.70.3108
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

    Roeker, Lindsey E / Fox, Christopher P / Eyre, Toby A / Brander, Danielle M / Allan, John N / Schuster, Stephen J / Nabhan, Chadi / Hill, Brian T / Shah, Nirav N / Lansigan, Frederick / Yazdy, Maryam / Cheson, Bruce D / Lamanna, Nicole / Singavi, Arun K / Coombs, Catherine C / Barr, Paul M / Skarbnik, Alan P / Shadman, Mazyar / Ujjani, Chaitra S /
    Tuncer, Hande H / Winter, Allison M / Rhodes, Joanna / Dorsey, Colleen / Morse, Hannah / Kabel, Charlene / Pagel, John M / Williams, Annalynn M / Jacobs, Ryan / Goy, Andre / Muralikrishnan, Sivraj / Pearson, Laurie / Sitlinger, Andrea / Bailey, Neil / Schuh, Anna / Kirkwood, Amy A / Mato, Anthony R

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2019  Volume 25, Issue 14, Page(s) 4264–4270

    Abstract: Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of ...

    Abstract Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact of dosing modifications in routine clinical practice.
    Experimental design: This retrospective cohort study included 297 CLL venetoclax-treated patients outside of clinical trials in academic and community centers. Demographics, baseline disease characteristics, venetoclax dosing, TLS risk and prophylaxis, and AEs were collected.
    Results: The group was 69% male, 96% had relapsed/refractory CLL, 45% had deletion chromosome 17p, 84% had unmutated
    Conclusions: These data provide insights into current use of venetoclax in clinical practice, including TLS rates observed in clinical practice. We identified opportunities for improved adherence to TLS risk stratification and prophylaxis, which may improve safety.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Patient Safety ; Practice Patterns, Physicians'/standards ; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors ; Retrospective Studies ; Sulfonamides/therapeutic use ; Treatment Outcome ; Tumor Lysis Syndrome/prevention & control
    Chemical Substances Antineoplastic Agents ; BCL2 protein, human ; Bridged Bicyclo Compounds, Heterocyclic ; Proto-Oncogene Proteins c-bcl-2 ; Sulfonamides ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2019-04-19
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-19-0361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top